If you've been managing PMDD and wondering what treatment options exist beyond SSRIs, this review brings encouraging news about a potential new medication approach.
SSRIs (like sertraline or fluoxetine) remain the go-to first-line treatment for PMDD, and they work faster for PMDD than for depression — often within days rather than weeks. This means some people can take them only during the luteal phase (the two weeks before their period) instead of every day. However, SSRIs don't work for everyone, and about half of people stop taking them within six months due to side effects or other reasons.
The most exciting finding discussed here involves a medication called ulipristal acetate, which is a type of selective progesterone receptor modulator (SPRM). In a clinical trial of 95 women with PMDD, about 85% of those who took this medication experienced significant improvement in their mood symptoms over three months, and half achieved complete recovery — compared to only 21% on placebo. The medication was especially helpful for symptoms like anger, irritability, and depression, though it didn't significantly help with physical symptoms like bloating or breast tenderness. Side effects were mild and uncommon.
This medication works by blocking progesterone receptors in the body and brain, which keeps progesterone levels low and stable while maintaining healthy estrogen levels. Since PMDD appears to be caused not by abnormal hormone levels but by the brain being overly sensitive to normal hormone fluctuations, stabilizing these fluctuations may prevent symptoms from being triggered. Brain imaging studies also suggest the treatment helps restore healthy patterns of emotion regulation in the brain. While these results are promising, this was a proof-of-concept study, and more research is needed on long-term safety before it could become a standard treatment option.
Key findings
- A proof-of-concept RCT (N=95) of ulipristal acetate (a selective progesterone receptor modulator) showed that 85% of treated subjects experienced complete or partial remission of PMDD symptoms over 3 months, compared with 21% complete recovery in the placebo group
- SPRM treatment specifically improved mental symptoms such as anger, irritability, and depression, but did not significantly affect somatic symptoms
- SSRIs achieve clinical efficacy within days in PMDD (unlike weeks for depression), enabling intermittent luteal-phase-only dosing, but nearly half of individuals with PMDD discontinue SSRIs within the first 6 months
- SPRM treatment resulted in anovulation with low progesterone levels while maintaining oestradiol at mid-follicular phase levels, with side effects that were rare and generally mild (headache, nausea, fatigue)
- Neuroimaging evidence suggests SPRM treatment is associated with enhanced reactivity in the dorsal anterior cingulate cortex and dorsomedial prefrontal cortex, indicating improved top-down emotion regulation
- PMDD prevalence is approximately 5% across countries and is stable over time, with subthreshold cases being many times more prevalent
Methods, briefly
Narrative review synthesizing evidence from published clinical trials, neuroimaging studies, and systematic reviews on PMDD pathophysiology and pharmacological treatments. Key referenced trial: multi-centre, double-blind, placebo-controlled RCT of ulipristal acetate (N=95) over 3 months. No new primary data collected.
Limitations to keep in mind
- This is a narrative review, not a systematic review, so study selection may be subject to bias
- The SPRM proof-of-concept trial had a relatively small sample size (N=95) and was only 3 months in duration
- Long-term efficacy, safety, and viability of SPRMs in reproductive-age women remain unknown
- Concerns about liver safety with SPRMs noted from studies in older females with uterine fibroids have not been fully addressed for the PMDD population
- Much of the neuroimaging evidence cited involves small sample sizes and methodological limitations acknowledged by the authors
The latest PMDD research, in your pocket
The app’s research feed is updated daily with newly published, peer-reviewed PMDD work - summarized in plain language.